Vis enkel innførsel

dc.contributor.authorYanes, M.
dc.contributor.authorSantoni, Giola
dc.contributor.authorMaret-Ouda, John
dc.contributor.authorNess-Jensen, E.
dc.contributor.authorFärkkilä, Martti
dc.contributor.authorLynge, Elsebeth
dc.contributor.authorPukkala, Eero
dc.contributor.authorRomundstad, P.
dc.contributor.authorTryggvadottir, Laufey
dc.contributor.author-Chelpin, M von Euler
dc.contributor.authorLagergren, Jesper
dc.date.accessioned2022-03-10T12:04:02Z
dc.date.available2022-03-10T12:04:02Z
dc.date.created2021-09-06T13:31:06Z
dc.date.issued2021
dc.identifier.citationBritish Journal of Surgery. 2021, 108 (7), 864-870.en_US
dc.identifier.issn0007-1323
dc.identifier.urihttps://hdl.handle.net/11250/2984252
dc.description.abstractBackground The aim was to examine the hypothesis that antireflux surgery with fundoplication improves long-term survival compared with antireflux medication in patients with reflux oesophagitis or Barrett’s oesophagus. Method Individuals aged between 18 and 70 years with reflux oesophagitis or Barrett’s oesophagus (intestinal metaplasia) documented from in-hospital and specialized outpatient care were selected from national patient registries in Denmark, Finland, Iceland, and Sweden from 1980 to 2014. The study investigated all-cause mortality and disease-specific mortality, comparing patients who had undergone open or laparoscopic antireflux surgery with fundoplication versus those using antireflux medication. Multivariable Cox regression analysis was used to estimate hazard ratios (HRs) with 95 per cent confidence intervals for all-cause mortality and disease-specific mortality, adjusted for sex, age, calendar period, country, and co-morbidity. Results Some 240 226 patients with reflux oesophagitis or Barrett’s oesophagus were included, of whom 33 904 (14.1 per cent) underwent antireflux surgery. The risk of all-cause mortality was lower after antireflux surgery than with use of medication (HR 0.61, 95 per cent c.i. 0.58 to 0.63), and lower after laparoscopic (HR 0.56, 0.52 to 0.60) than open (HR 0.80, 0.70 to 0.91) surgery. After antireflux surgery, mortality was decreased from cardiovascular disease (HR 0.58, 0.55 to 0.61), respiratory disease (HR 0.62, 0.57 to 0.66), laryngeal or pharyngeal cancer (HR 0.35, 0.19 to 0.65), and lung cancer (HR 0.67, 0.58 to 0.80), but not from oesophageal cancer (HR 1.05, 0.87 to 1.28), compared with medication, The decreased mortality rates generally remained over time. Conclusion In patients with reflux oesophagitis or Barrett’s oesophagus, antireflux surgery is associated with lower mortality from all causes, cardiovascular disease, respiratory disease, laryngeal or pharyngeal cancer, and lung cancer, but not from oesophageal cancer, compared with antireflux medication.en_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.titleSurvival after antireflux surgery versus medication in patients with reflux oesophagitis or Barrett's oesophagus: multinational cohort studyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.rights.holderThis is the authors' accepted manuscript to an article published by Oxford University Pressen_US
dc.source.pagenumber864-870en_US
dc.source.volume108en_US
dc.source.journalBritish Journal of Surgeryen_US
dc.source.issue7en_US
dc.identifier.doi10.1093/bjs/znab024
dc.identifier.cristin1931631
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel